Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

In vivo platelet activation and platelet hyperreactivity in abacavir-treated HIV-infected patients.

Falcinelli E, Francisci D, Belfiori B, Petito E, Guglielmini G, Malincarne L, Mezzasoma A, Sebastiano M, Conti V, Giannini S, Bonora S, Baldelli F, Gresele P.

Thromb Haemost. 2013 Aug;110(2):349-57. doi: 10.1160/TH12-07-0504. Epub 2013 May 23.

PMID:
23703656
2.

Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir.

Saumoy M, Ordoñez-Llanos J, Martínez E, Barragán P, Ribera E, Bonet R, Knobel H, Negredo E, Loncá M, Curran A, Gatell JM, Podzamczer D; Bicombo-met Substudy Team..

Antivir Ther. 2011;16(4):459-68. doi: 10.3851/IMP1785.

PMID:
21685533
3.

Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1-infected patients.

Goicoechea M, Jain S, Bi L, Kemper C, Daar ES, Diamond C, Ha B, Flaherty J, Sun S, Richman D, Louie S, Haubrich R; California Collaborative Treatment Group..

AIDS. 2010 Mar 13;24(5):707-16. doi: 10.1097/QAD.0b013e32833676eb.

PMID:
20087154
4.

Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir.

Maggi P, Montinaro V, Bellacosa C, Pietanza S, Volpe A, Graziano G, Strippoli GF, Angarano G.

AIDS Patient Care STDS. 2012 Jan;26(1):5-11. doi: 10.1089/apc.2011.0185. Epub 2011 Dec 2.

PMID:
22136504
5.

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.

Smith KY, Patel P, Fine D, Bellos N, Sloan L, Lackey P, Kumar PN, Sutherland-Phillips DH, Vavro C, Yau L, Wannamaker P, Shaefer MS; HEAT Study Team..

AIDS. 2009 Jul 31;23(12):1547-56. doi: 10.1097/QAD.0b013e32832cbcc2.

PMID:
19542866
6.

Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens.

Hawkins T, Veikley W, St Claire RL 3rd, Guyer B, Clark N, Kearney BP.

J Acquir Immune Defic Syndr. 2005 Aug 1;39(4):406-11.

PMID:
16010161
7.

Nitric oxide-dependent and independent effects on human platelets treated with peroxynitrite.

Brown AS, Moro MA, Masse JM, Cramer EM, Radomski M, Darley-Usmar V.

Cardiovasc Res. 1998 Nov;40(2):380-8.

PMID:
9893732
8.

Effect of clopidogrel treatment on stress-induced platelet activation and myocardial ischemia in aspirin-treated patients with stable coronary artery disease.

Perneby C, Wallén NH, Hofman-Bang C, Tornvall P, Ivert T, Li N, Hjemdahl P.

Thromb Haemost. 2007 Dec;98(6):1316-22.

PMID:
18064330
9.

Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclase.

Baum PD, Sullam PM, Stoddart CA, McCune JM.

AIDS. 2011 Nov 28;25(18):2243-8. doi: 10.1097/QAD.0b013e32834d3cc3.

10.

A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.

Martínez E, Arranz JA, Podzamczer D, Loncá M, Sanz J, Barragán P, Ribera E, Knobel H, Roca V, Gutiérrez F, Blanco JL, Mallolas J, Llibre JM, Clotet B, Dalmau D, Segura F, Arribas JR, Cosín J, Barrufet P, Casas E, Ferrer E, Curran A, González A, Pich J, Cruceta A, Arnaiz JA, Miró JM, Gatell JM; BICOMBO Study Team..

J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):290-7. doi: 10.1097/QAI.0b013e3181aa12d5.

PMID:
19398921
11.

Relationships between optical aggregometry (type born) and flow cytometry in evaluating ADP-induced platelet activation.

Sbrana S, Della Pina F, Rizza A, Buffa M, De Filippis R, Gianetti J, Clerico A.

Cytometry B Clin Cytom. 2008 Jan;74(1):30-9.

12.

Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study.

O'Brien M, Montenont E, Hu L, Nardi MA, Valdes V, Merolla M, Gettenberg G, Cavanagh K, Aberg JA, Bhardwaj N, Berger JS.

J Acquir Immune Defic Syndr. 2013 Jul 1;63(3):280-8. doi: 10.1097/QAI.0b013e31828a292c.

13.

Differential effects of tenofovir/emtricitabine and abacavir/lamivudine on human leukocyte recruitment.

De Pablo C, Orden S, Calatayud S, Martí-Cabrera M, Esplugues JV, Alvarez A.

Antivir Ther. 2012;17(8):1615-9. doi: 10.3851/IMP2357. Epub 2012 Sep 7.

PMID:
22954798
14.

Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging.

Leeansyah E, Cameron PU, Solomon A, Tennakoon S, Velayudham P, Gouillou M, Spelman T, Hearps A, Fairley C, Smit de V, Pierce AB, Armishaw J, Crowe SM, Cooper DA, Koelsch KK, Liu JP, Chuah J, Lewin SR.

J Infect Dis. 2013 Apr;207(7):1157-65. doi: 10.1093/infdis/jit006. Epub 2013 Jan 9.

PMID:
23303810
15.

Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction.

Martínez E, Larrousse M, Podzamczer D, Pérez I, Gutiérrez F, Loncá M, Barragán P, Deulofeu R, Casamitjana R, Mallolas J, Pich J, Gatell JM; BICOMBO Study Team..

AIDS. 2010 Jan 28;24(3):F1-9. doi: 10.1097/QAD.0b013e32833562c5.

PMID:
20009917
16.

Reduced platelet hyperreactivity and platelet-monocyte aggregation in HIV-infected individuals receiving a raltegravir-based regimen.

Tunjungputri RN, Van Der Ven AJ, Schonsberg A, Mathan TS, Koopmans P, Roest M, Fijnheer R, Groot PG, de Mast Q.

AIDS. 2014 Sep 10;28(14):2091-6. doi: 10.1097/QAD.0000000000000415.

PMID:
25265076
17.

Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir.

Padilla S, Masiá M, García N, Jarrin I, Tormo C, Gutiérrez F.

BMC Infect Dis. 2011 Feb 4;11:40. doi: 10.1186/1471-2334-11-40.

18.

Increased platelet reactivity in HIV-1-infected patients receiving abacavir-containing antiretroviral therapy.

Satchell CS, O'Halloran JA, Cotter AG, Peace AJ, O'Connor EF, Tedesco AF, Feeney ER, Lambert JS, Sheehan GJ, Kenny D, Mallon PW.

J Infect Dis. 2011 Oct 15;204(8):1202-10. doi: 10.1093/infdis/jir509.

PMID:
21917893
19.

Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons.

Choi AI, Vittinghoff E, Deeks SG, Weekley CC, Li Y, Shlipak MG.

AIDS. 2011 Jun 19;25(10):1289-98. doi: 10.1097/QAD.0b013e328347fa16.

20.

Suppressed anti-aggregating and cGMP-elevating effects of sodium nitroprusside in platelets from patients with stable angina pectoris.

Chirkov YY, Chirkova LP, Horowitz JD.

Naunyn Schmiedebergs Arch Pharmacol. 1996 Oct;354(4):520-5.

PMID:
8897457

Supplemental Content

Support Center